Breaking News
July 20, 2018 - Immediate Monitoring With ECG Patch Ups A-Fib Diagnosis Rate
July 20, 2018 - Scientists seek to better protect the eye from glaucoma
July 20, 2018 - Football training could improve bone mineral density in prostate cancer patients
July 20, 2018 - Single genetic change in gut bacteria can lead to obesity
July 20, 2018 - Research uncovers new target for therapeutic intervention in breast cancer
July 20, 2018 - WFN to highlight clean air for brain health on World Brain Day 2018
July 20, 2018 - Health Highlights: July 17, 2018
July 20, 2018 - Mom’s marijuana winds up in breast milk
July 20, 2018 - Black men could be healthier if seen by black physicians, new research suggests
July 20, 2018 - Alcoholics have persistent difficulties with emotional communication after long-term abstinence
July 19, 2018 - Researchers unravel how ALL invades the central nervous system
July 19, 2018 - Mother’s microbiome determines offspring’s risk of developing autism
July 19, 2018 - Refining standards of maternal-fetal care
July 19, 2018 - Stitching single cells together any which way you want to
July 19, 2018 - Study identifies RNA molecules that regulate male hormones in prostate cancer
July 19, 2018 - New machine-learning model shows promise in predicting undiagnosed dementia
July 19, 2018 - Sleep supports antioxidant processes, study suggests
July 19, 2018 - MiRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
July 19, 2018 - Unique brain ‘fingerprint’ can predict drug effectiveness
July 19, 2018 - Life on the border: Struggling to survive in Jordan
July 19, 2018 - CT scans may raise brain tumor risk
July 19, 2018 - Moderate alcohol intake linked with improved male fertility
July 19, 2018 - Alcohol-related cirrhosis mortality on the rise among young adults
July 19, 2018 - Study uncovers new protein complex that shields broken DNA ends
July 19, 2018 - Regular sunscreen use protects young people from melanoma
July 19, 2018 - Using non-invasive brain recordings to characterize activity in deep structures
July 19, 2018 - Mediterranean diet could influence academic performance through effects on sleep quality
July 19, 2018 - Woman’s pregnancy history may be linked to Alzheimer’s disease risk
July 19, 2018 - Study calls for new gold standard in research to treat non-alcoholic steatohepatitis
July 19, 2018 - Cancer patients receiving anti-PD-1 therapies may experience delayed skin reactions
July 19, 2018 - Scientists study adverse effects of carbon, silicon nanotubes and carbon nanofibers
July 19, 2018 - Keck Hospital of USC receives Magnet recognition for excellence in nursing
July 19, 2018 - Scientists identify hidden signals in RNAs that control protein synthesis
July 19, 2018 - Quadrivalent HPV Vaccine Not Tied to Spontaneous Abortion
July 19, 2018 - FDA OKs first drug made to reduce excessive sweating
July 19, 2018 - New Finnish study compares surgical treatment of shoulder impingement syndrome to placebo surgery
July 19, 2018 - New findings do no support caffeine as effective appetite suppressant or weight-loss aid
July 19, 2018 - Kite collaborates with Gadeta to develop novel gamma delta TCR therapies for various cancers
July 19, 2018 - Study evaluates Neoteryx’s VAMS technology for monitoring HbA1c levels of diabetic children
July 19, 2018 - New clinical trial examines use of adrenaline to treat cardiac arrests
July 19, 2018 - Early surgical intervention may improve outcomes for patients with mitral valve disease
July 19, 2018 - Prolonged preoperative opioid use linked to adverse outcomes after total knee and hip arthroplasty
July 19, 2018 - Biophysicists use infrared sensor as new method for drug discovery
July 19, 2018 - Rat study shows negative effects of perinatal exposure to phthalates
July 19, 2018 - Children with disabilities endure long waits for life-changing medical equipment
July 19, 2018 - Ways to stay safe while camping and hiking
July 19, 2018 - People with HIV twice as likely to suffer from heart disease
July 19, 2018 - On-the-Job Stress Relief – Drugs.com MedNews
July 19, 2018 - Compounds found in green tea and wine may block formation of toxic metabolites
July 19, 2018 - Gene regulator associated with protein pileup in exfoliation glaucoma
July 19, 2018 - Trump administration summons immigrant infants
July 19, 2018 - FDA grants approval for first breast cancer drug through ‘Real-Time Oncology Review’
July 19, 2018 - Five tips for men seeking plastic surgery
July 19, 2018 - Researchers discover the reasons why some people get dizzy when hearing certain sounds
July 19, 2018 - Research project investigates snake venom treatment as antibiotic alternative for eye infections
July 19, 2018 - Melanoma could soon be detected using a blood test
July 19, 2018 - Exposure to bright light may have big impact on sleep-related behavior in children
July 19, 2018 - Deleting single gene in gut bacteria affects metabolism, reduces weight gain in mice
July 19, 2018 - New proteomics studies help gain more insights into Alzheimer’s, cancer and listeriosis
July 19, 2018 - Study finds major discrepancies in prescription drug labeling pregnancy information across four countries
July 19, 2018 - Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 19, 2018 - Watching the immune system in action reveals what happens when things goes wrong
July 19, 2018 - Increasing blood sugar levels improves memory and performance in older adults
July 19, 2018 - Connection between self-regulation and obesity appears to be different for girls and boys
July 19, 2018 - Researchers develop new, less destructive method for whitening teeth
July 19, 2018 - Revving up innate control of viral infection requires a three-cell ignition
July 19, 2018 - Inaccurate direct-to-consumer raw genetic data can harm patients, new research suggests
July 19, 2018 - Weight loss surgery is effective under the right situations
July 19, 2018 - BioTek awarded patent for autofocus feature on microplate reader
July 19, 2018 - Low-carb diets reduce stiffness of arteries in women and promote weight loss in men
July 19, 2018 - New review examines cannabinoids’ potential for direct treatment of cancer
July 19, 2018 - Allergic responses may help protect the skin against cancer, research suggests
July 19, 2018 - Inappropriate Prescribing of Abx High in Urgent Care Centers
July 19, 2018 - Many at risk for HIV despite lifesaving pill
July 19, 2018 - Tips for doctors and parents on the harms of marijuana use for teens
July 18, 2018 - Researchers detect presence of IgE antibodies after kidney transplantation
July 18, 2018 - New technique allows researchers to create large scale, personalized bone grafts
July 18, 2018 - Smoking May Boost Atrial Fibrillation Risk
July 18, 2018 - Genome editing method targets AIDS virus
July 18, 2018 - These things matter: Medical complications are not inevitable, a physician writes
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

image_pdfDownload PDFimage_print

HASBROUCK HEIGHTS, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.

The article is entitled “Fexapotide Triflutate: Results of Long-Term Safety and Efficacy Trials of a Novel Injectable Therapy for Symptomatic Prostate Enlargement” and is authored by 17 leading U.S. urologists:

Neal Shore, MD, FACS (Carolina Urologic Research Center, Myrtle Beach, SC);
Ronald Tutrone, MD, FACS (Chesapeake Urology Research Associates, Baltimore, MD);
Mitchell Efros, MD, FACS (Accumed Research, Garden City, NY);
Mohamed Bidair, MD (San Diego Clinical Trials, San Diego, CA);
Barton Wachs, MD (Atlantic Urology Medical Group, Long Beach, CA);
Susan Kalota, MD (Urological Associates of Southern Arizona, Tucson, AZ);
Sheldon Freedman, MD, FACS (Freedman Urology, Las Vegas, NV);
James Bailen, MD, FACS (First Urology, Louisville, KY);
Richard Levin, MD, FACS (Chesapeake Urology Research Associates, Towson, MD);
Stephen Richardson, MD (Jean Brown Research, Salt Lake City, UT);
Jed Kaminetsky, MD, FACS (University Urology, New York, NY);
Jeffrey Snyder, MD, FACS (Genitourinary Surgical Consultants, Denver, CO);
Barry Shepard, MD, FACS (Urological Surgeons of Long Island, Garden City, NY);
Kenneth Goldberg, MD, FACS (U T Southwestern Dept of Urology, Lewisville, TX);
Alan Hay, MD, FACS (Willamette Urology, Salem, OR);
Steven Gange, MD, FACS (Summit Urology Group, Salt Lake City, UT);
Ivan Grunberger, MD, FACS (Brooklyn Urology, Brooklyn, NY).
The full peer review publication is available online on the World Journal of Urology’s website.

World Journal of Urology is a prestigious top-tier international peer review journal specialized in clinical urology.

According to the new publication, “In conclusion, data from these 4 U.S. studies show statistically significant long-term improvement in BPH symptoms and objective outcomes including significant reduction in spontaneous AUR as well as the addition of BPH surgery;” and “FT is well tolerated with an excellent safety profile. Hence, FT is a safe and efficacious clinic based treatment for BPH involving an intraprostatic injection that requires only a few minutes to administer, with no catheter nor anesthesia requirements. FT injectable represents a novel, first in class BPH treatment modality.”

The lead author of the article, Dr. Neal Shore, said, “FT represents a new first in class treatment for patients with lower urinary tract symptoms and BPH. FT administration via direct intraprostatic injection is ideally suited for the urology clinic. The collective trial data demonstrates both short and long-term safety for FT; moreover, the long-term efficacy data demonstrates its major potential as an alternative to conventional daily oral BPH medications.”

Dr. Ronald Tutrone, a co-author of the report, said, “The co-authors and urologists with whom I have spoken and who have attended presentations of data are very impressed with the results. I personally know of countless patients who will benefit from this new, non-surgical treatment.”

Reprints of the article will also be available later from Nymox upon request after reprints become available from the publisher.

Fexapotide has shown significant long-term benefit for prostate enlargement (benign prostatic hyperplasia, BPH). The recent results of Phase 3 studies of Fexapotide for BPH were communicated in podium and symposium presentations to the American Urological Association at four recent sectional Annual Meetings in 2017 in Scottsdale, AZ (North Central AUA November 15, 2017); Havana, Cuba (New York AUA November 6, 2017); Naples, FL (South Central AUA November 27, 2017) and Savannah, GA (Northeastern AUA October 12, 2017). The Company has filed for approval for Fexapotide in Europe for BPH for prostate enlargement in 2017, and the filing was validated in September 2017.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on Fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.

Source: Nymox Pharmaceutical Corporation

Posted: January 2018

Tagged with:

About author

Related Articles